---
schema_version: "secwatch.filing_event.v1"
accession: "0001701541-24-000020"
form_type: "8-K"
ticker: "BDTX"
cik: "0001701541"
company_name: "Black Diamond Therapeutics, Inc."
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T06:27:29.095405+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Black Diamond Q1 net loss $18.2M; cash $115.2M; Phase 2 BDTX-1535 data on track for Q3 2024

## Summary
- Net loss of $18.2M for Q1 2024 vs $20.9M in Q1 2023; R&D exp $13.5M, G&A $6.7M.
- Cash, equivalents, investments $115.2M as of Mar 31, 2024; runway into Q3 2025.
- Phase 2 BDTX-1535 in 2L/3L EGFRm NSCLC initial data expected Q3 2024; 1L cohort enrollment ongoing, data Q1 2025.
- ASCO June 1: Phase 1 BDTX-1535 GBM dose-escalation and window-of-opportunity trial results.
- Board changes: Shannon Campbell and Prakash Raman appointed; Wendy Dixon and Alex Mayweg stepped down.

## SEC filing metadata
- accession: 0001701541-24-000020
- form_type: 8-K
- ticker: BDTX
- cik: 0001701541
- company_name: Black Diamond Therapeutics, Inc.
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1701541/000170154124000020/0001701541-24-000020-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1701541/000170154124000020/bdtx-20240509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001701541-24-000020
- JSON: https://secwatch.observer/filing/0001701541-24-000020.json
- Plain text: https://secwatch.observer/filing/0001701541-24-000020.txt

## Key facts
- Earnings Releases
  Black Diamond Therapeutics, Inc. reported the first quarter ended March 31, 2024 results: net income $18.2 million.
  - Period: the first quarter ended March 31, 2024
  - Net income: $18.2 million
  - Result: reported results
  source text: Net loss for the first quarter of 2024 was $18.2 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1701541/000170154124000020/0001701541-24-000020-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.